Melanoma
PD-L1 IHC 22C3 pharmDx for Autostainer Link 48
Non-small cell lung cancer (NSCLC)
PD-L1 protein expression in NSCLS is determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. The specimen should be considered to have PD-L1 expression if TPS ≥ 1% and high PD-L1 expression if TPS ≥ 50%.
PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA® (pembrolizumab).
Melanoma
PD-L1 IHC 22C3 pharmDx may be used to determine PD-L1 status in melanoma patients being considered for treatment.
PD-L1 IHC 22C3 pharmDx kit
The kit includes reagents required for the immunohistochemical staining (except wash buffer), control slides representing different expression levels of PD-L1 protein, and detailed instructions. The kit has been tailored especially for use on Autostainer Link 48 instruments. The materials provided are sufficient for 50 tests (50 slides incubated with monoclonal mouse antibody to PD-L1 and 50 slides incubated with the corresponding negative control reagent, 100 slides in total).
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Read more about PD-L1 IHC 22C3 pharmDx.
Reg. Status: CE-IVD